Fig 3.

Change in PaO₂/FiO₂ in patients with COVID-19 treated early (before 11 days of symptoms onset) or late with TCZ and not treated. A, Patients with high baseline IL-6 (cutoff 30 pg/mL). B, Subjects with low baseline IL-6 serum levels. Data in A and B are shown as the IQR (p75 upper edge, p25 lower edge, p50 midline), p95 (line above the box), and p5 (line below the box) before (gray boxes) and after (white boxes) treatment with TCZ. In nontreated patients, PRE and POST mean first and second evaluation, respectively. Statistical significance was determined with the Mann-Whitney test. C, The graph represents the predicted mean (dots) with 95% CI (bars) of PaO₂/FiO₂ according to baseline IL-6 levels and early or late TCZ treatment. Data were obtained with the command marginsplot of Stata, after adjustment by baseline PaO₂/FiO₂ and radiological pattern, hypertension, LDH and CRP levels, lymphocyte blood count, and need for IMV, according to the multivariable analysis displayed in Table E2 (see the Methods section for further information).